Valuations, however, seem to have factored in most of the gains
Investors are banking on early resolution of FDA issues
While HMS acquisition will add to company's pharmacy business, hospital segment will drive profits
Muted growth likely this year on sharp rise in genset prices
Improved sales in NCR will help improve cash flows, reduce debt
While increasing competition is impacting its pricing power, ad revenue growth has been lagging peers such as Zee Entertainment
2014 has been a year of mid-cap stocks. Quite a few can run up even higher
Rising competition impacting its pricing power and ad revenue growth has been lagging major peers
A financial turnaround with Etihad partnership and debt restructuring has not yet fully materialised
CVs yet to fire, though mgmt and analysts are optimistic, with upbeat estimates
Company having a hard time coping with demand surge for Bullet and Classic that have waiting periods of 4-5 months
A recovery in the commercial vehicle segment, coupled with progress of the company's non-automobile business, should see domestic revenue catch up
Home market has been sluggish for a while but this is expected to change, as reflected in the scrip's steady rise; management has aggressive plans
The volume and market share gains can be attributed to a series of launches, especially in the second half of 2013-14
Product launches, presence in high-growth markets and lower debt should help it improve revenue, earnings growth
Increasing auto volumes, focus on replacement segment and lower lead prices to help improve utilisation and margins
Oversupply of natural rubber and higher demand for tyres should aid revenue and profitability
Strong growth, led by demand recovery, entry into new segments and uptick in margins, should double net profit by FY17
Street not perturbed over rising competition for products in US, as overall pipeline remains strong